News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Oruka reported Phase 2 durability data for ORKA-001 that supports ultra-long-dose positioning.
  • The ORKA-001 readout implies potential re-rating of Oruka stock and commercial upside in psoriasis biologics.
  • Trade recommendation: buy Oruka with entry $72.01, stop $58.00, target $130.00 over 180 trading days.
  • Adyen is pivoting to a platform-led checkout model to capture higher fees and increase merchant retention.
  • That strategic shift should raise Adyen's margins and support stronger revenue per merchant, improving valuation prospects.
  • Analysts outline a long Adyen position with explicit entry, stop and target levels.

Latest Articles

Aeluma Executes Strategic Agreement with Sumitomo Chemical Advanced Technologies for Wafer Production for AI Datacom

Aeluma Executes Strategic Agreement with Sumitomo Chemical Advanced Technologies for Wafer Production for AI Datacom

Aeluma, Inc. has entered into a strategic agreement with Sumitomo Chemical Advanced Technologies (SCAT) to accelerate the development and production of photonics wafers for the AI datacom market. This partnership leverages SCAT's existing MOCVD manufacturing capabilities to increase capacity and reduce dependency on limited InP substrates by utiliz…

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

BlossomHill Therapeutics announced encouraging updated data from its Phase 1/2 SOLARA trial of BH-30643, an investigational OMNI-EGFR inhibitor, in patients with EGFR C797S-positive non-small cell lung cancer (NSCLC). The therapy demonstrated a 45% objective response rate and 88% disease control rate in this difficult-to-treat population, along wit…

Bread Financial Provides Performance Update for August 2026

Bread Financial Provides Performance Update for August 2026

Bread Financial Holdings, Inc. provided its August 2026 performance update showing a 5.6% year-over-year increase in average credit card and other loans and an improvement in credit quality metrics, including a decline in net principal loss rate to 6.40% from 7.57% and a lower delinquency rate of 5.36% compared to 5.84% last year. The company conti…

Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™

Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™

Quantum-Si Incorporated announced a significant milestone in protein sequencing technology by demonstrating the ability to detect 18 amino acids using their Proteus™ developmental sequencing kit. The company maintains confidence in achieving detection of all 20 amino acids by the end of 2026, enhancing their product launch prospects for this innova…

GeoPark Limited Announces Commencement of Consent Solicitation with Respect to Its 8.750% Senior Notes Due 2030

GeoPark Limited Announces Commencement of Consent Solicitation with Respect to Its 8.750% Senior Notes Due 2030

GeoPark Limited announced a consent solicitation for its 8.750% Senior Notes due 2030 to amend the indenture definition of "Permitted Holders" to include major shareholder Jaime Gilinski Bacal and his affiliates. This move relates to Grupo Gilinski's recent significant share acquisition and their lead role in GeoPark's planned entry into Venezuela …

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

Connect Biopharma announced positive topline data from its global Phase 2 Seabreeze STAT Asthma study evaluating rademikibart, an anti-IL-4Rα antibody, as an add-on treatment for acute exacerbations in adult and adolescent asthma patients with type 2 inflammation. The study demonstrated a 66% reduction in treatment failure rate at 28 days (though n…

Art Meets Whiskey: Breckenridge Distillery Debuts Limited-Edition Collectors Series Release with Pat Milbery

Art Meets Whiskey: Breckenridge Distillery Debuts Limited-Edition Collectors Series Release with Pat Milbery

Breckenridge Distillery, owned by Tilray Brands, introduces the sixth edition of its Collectors Art Series with a limited-edition Barbados Cask Finish whiskey featuring artwork by Colorado muralist Pat Milbery. The release celebrates the blend of art and whiskey craftsmanship and supports the creative community through charitable giving. Milbery's …

Onity Group to Host Its First Investor Day Event on November 19, 2026

Onity Group to Host Its First Investor Day Event on November 19, 2026

Onity Group Inc., a leading U.S.-based non-bank financial services company specializing in mortgage servicing and originations, announced it will hold its first Investor Day on November 19, 2026 in New York. The company plans to present its strategies for enhancing customer experience and achieving sustainable growth. The event will feature present…

Markets on Edge as Treasury Yields Surge and Officials Head to the Hill

Markets on Edge as Treasury Yields Surge and Officials Head to the Hill

Global markets opened the week under pressure as the U.S. 10-year Treasury yield climbed above 5% to its highest level in 19 years, energy prices rose past $107 a barrel and Japanese 10-year yields moved back above 3%. Treasury Secretary Scott Bessent is scheduled to testify before the House Financial Services Committee as the Federal Reserve begin…

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Vera Therapeutics announced TRUTAKNA (atacicept-vymj), the first FDA-approved BAFF and APRIL inhibitor, successfully stabilized estimated glomerular filtration rate (eGFR) and significantly reduced kidney disease progression over two years in the ORIGIN 3 Phase 3 trial for adults with IgA nephropathy (IgAN). The therapy showed a favorable safety pr…

Ducommun Incorporated Announces Follow-On Award of Significant Content Supporting PAC-3 MSE Missile Platform

Ducommun Incorporated Announces Follow-On Award of Significant Content Supporting PAC-3 MSE Missile Platform

Ducommun Incorporated announced a follow-on contract worth over $35 million from Simmonds Precision Products to provide electronic assemblies for Lockheed Martin's PAC-3 missile family. This award supports the company's focus on expanding its defense business and advancing its long-term growth strategy, with production centered at its Tulsa, Oklaho…